Beam Therapeutics Q1 net loss narrows beating analyst estimates

Beam Therapeutics

07/05/2026 12:14

Overview

US gene editing biotech's Q1 net loss narrowed, beating analyst expectations

Operating loss for Q1 was smaller than expected, beating analyst forecasts

License and collaboration revenue more than quadrupled yr/yr

Outlook

Beam expects to initiate BEAM-302 pivotal cohort in AATD in second half of 2026

Company anticipates submitting BLA for risto-cel as early as year-end 2026

Beam expects cash runway to support operations into mid-2029

Result Drivers

LICENSE AND COLLABORATION REVENUE - Q1 revenue more than quadrupled yr/yr, driven by increased license and collaboration activity

PIPELINE INVESTMENT - Higher R&D and G&A expenses reflect ongoing investment in clinical programs and corporate activities

Company press release: ID:nGNX4S6pFq

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 License and Collaboration Revenue
$31.74 mln
Q1 Net Income
Beat
-$94.32 mln
-$112.26 mln (13 Analysts)
Q1 Operating Income
Beat
-$107.22 mln
-$122.23 mln (12 Analysts)
Q1 Operating Expenses
$138.95 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Beam Therapeutics Inc is $46.00, about 42.2% above its May 6 closing price of $32.34

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)